A Multi-center, Randomized, Blinded, Active-controlled, Phase 3 Clinical Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Co-administered with Hexavalent Vaccine At 2, 4 and 12-15 Months of Age to Healthy Infants in Indonesia
Latest Information Update: 01 Oct 2024
Price :
$35 *
At a glance
- Drugs Pneumococcal 13 valent vaccine conjugate-Beijing-Minhai-Biotechnology (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors Beijing Minhai Biotechnology
- 01 Oct 2024 New trial record